ClinicalTrials.gg
Not yet recruitingNCT07717775Updated Jul 27, 2026

A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults

A Phase 1 interventional study of AD-234 and AD-2341 in Gastritis, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.

Planned enrollment
25th of 25
30 · median 242
Started
2026
the only one that year
Phase 1
5 of 32
1 open now
Registered
32nd of 32
by date
Lead sponsor
3 of 32
Addpharma Inc.

Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 1, and was the 32nd registered.

Gastritis

135 studies on the registry are indexed under Gastritis; 23 are open to participants now.

Browse Gastritis studies →

Open to participants now

3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gastritis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.

Read the detailed description

The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-234 compared with AD-2341, AD-2342 in healthy subjects.

03

Conditions studied

  • Gastritis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening

    • Body weight between 50.0 kg and 90.0 kg, inclusive, and (BMI) between 18.5 kg/m\^2 and 29.9 kg/m\^2, inclusive, at the time of screening (BMI = weight [kg] / height [m]\^2)
    • For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm A(Vonoprazan, Fexuprazan, Vonoprazan)

    Participants receive AD-234 - AD-2341-AD-2342

    Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342

  • Experimental
    Arm B(Vonoprazan, Vonoprazan, Fexuprazan)

    Participants receive AD-234 - AD-2342- AD-2341

    Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342

  • Experimental
    Arm C(Fexuprazan, Vonoprazan, Vonoprazan)

    Participants receive AD-2341-AD-234-AD-2342

    Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342

  • Experimental
    Arm D(Fexuprazan, Vonoprazan, Vonoprazan)

    Participants receive AD-2341-AD-2342-AD-234

    Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342

  • Experimental
    Arm E(Vonoprazan, Vonoprazan, Fexuprazan)

    Participants receive AD-2342 -AD-234-AD-2341

    Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342

  • Experimental
    Arm F(Vonoprazan, Fexuprazan, Vonoprazan)

    Participants receive AD-2342-AD-2341-AD-234

    Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342

Interventions

  • DrugAD-234

    AD-234 tablet administered orally

  • DrugAD-2341

    AD-2341 tablet administered orally

  • DrugAD-2342

    AD-2342 tablet administered orally

06

What researchers measure

Primary outcomes

  1. Percent of Time With Gastric pH ≥4 During the 24-hour Interval After the 7th Dose

    Time frame: From pre-dose (0h) on Day 7 to 24 hours post-dose on Day 7 of each treatment period (Period 1: Day 7-Day 8; Period 2: Day 28-Day 29; Period 3: Day 49-Day 50)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartEst.
Aug 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07717775
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Aug 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 27, 2026

Study contacts

JaeHun Jung
Contact
jhjung@addpharma.co.kr
+82-31-891-5683

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion